Abiopharma

🔍 BABCOCK JOHN P (Executive)

Company: PEAPACK GLADSTONE FINANCIAL CORP (PGC)

Report Date: 2026-06-29

Detailed Transactions and Holdings:

• Sold 5,000 shares of Common Stock at $47.1065 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: false | shares_owned_after: 45,582.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-29 | Code: H | nature_of_ownership: Rabbi Trust | shares_owned_after: 74,876.00 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-29 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 6,720.00
• Holds 5,029 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 5,029.00 | Footnotes: F2, F2, F2
• Holds 9,362 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 9,362.00 | Footnotes: F3, F3, F3
• Holds 2,524 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 2,524.00 | Footnotes: F4, F4, F4
• Holds 4,788 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 4,788.00 | Footnotes: F5, F5, F5
• Holds 11,315 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 11,315.00 | Footnotes: F6, F6, F6
• Holds 14,043 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 14,043.00 | Footnotes: F7, F7, F7
• Holds 2,760 shares of Phantom Stock (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 2,760.00 | Footnotes: F8, F8, F8
• Holds 12,418 shares of Phantom Stock (Derivative)
  Date: 2026-06-29 | Code: H | shares_owned_after: 12,418.00 | Footnotes: F9, F9, F9
• Holds 16,000 shares of Phantom Rights (Derivative)
  Date: 2026-06-29 | Code: H | Expires: 2028-12-31 | shares_owned_after: 16,000.00 | Footnotes: F10, F10

Footnotes:

• F1: Held indirectly through a rabbi trust pursuant to a non-qualified deferred compensation plan.
• F2: On March 20, 2025, the reporting person was granted 7,543 restricted stock units (RSUs), vesting in three equal annual installments beginning on March 20, 2026. Upon vesting, each RSU converts into one share of PGC common stock.
• F3: On March 20, 2026, the reporting person was granted 9,362 restricted stock units (RSUs), vesting in three equal annual installments beginning on March 20, 2027. Upon vesting, each RSU converts into one share of PGC common stock.
• F4: On March 20, 2022, the reporting person was granted 12,588 restricted stock units (RSUs), vesting in five equal annual installments beginning on March 20, 2023. Upon vesting, each RSU converts into one share of PGC common stock.
• F5: On March 20, 2023, the reporting person was granted 11,970 restricted stock units (RSUs), vesting in five equal annual installments beginning on March 20, 2024. Upon vesting, each RSU converts into one share of PGC common stock.
• F6: On March 20, 2025, the reporting person was granted 11,315 restricted stock units (RSUs), vesting on the third anniversary of the grant if certain performance conditions are met. Upon vesting, each RSU converts into one share of PGC common stock.
• F7: On March 20, 2026, the reporting person was granted 14,043 restricted stock units (RSUs), vesting on the third anniversary of the grant if certain performance conditions are met. Upon vesting, each RSU converts into one share of PGC common stock.
• F8: On March 20, 2024, the reporting person was granted 8,278 phantom stock shares, vesting in three equal annual installments beginning on March 20, 2025. Upon vesting, each phantom share is the economic equivalent of one share of common stock.
• F9: On March 20, 2024, the reporting person was granted 12,418 phantom stock shares, vesting on the third anniversary of the grant if certain performance conditions are met. Upon vesting, each phantom share is the economic equivalent of one share of common stock.
• F10: Each performance right represents a contingent right to receive one share of PGC common stock. The performance rights vest upon PGC's common stock achieving a specified price per share.